• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DNMT1 Gene Record

  • Summary
  • Interactions
  • Claims
  • DNMT1 1786 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    1786
    DNA METHYLTRANSFERASE 1
    DNMT1
    ADCADN
    AIM
    CXXC9
    DNMT
    HSN1E
    MCMT
    m.HsaI
    126375
    2976
    ENSG00000130816
    OTTHUMG00000180397
    2605
    P26358
    DNMT1_HUMAN
    DNA (cytosine-5)-methyltransferase 1
    CXXC-type zinc finger protein 9
    DNA methyltransferase HsaI
    DNA MTase HsaI
    BE0000892
    1510
    DNA [cytosine-5]-methyltransferase
    T92308
    DNA [cytosine-5]-methyltransferase 1
    T88304
    NP_001124295
    NM_001130823

    Gene Info:

    Target Main Class Enzymes
    Target Subclass 2.1.1.37
    Target Class Enzymes
    Target Subclass EC:2.1.1.37
    Gene Biotype PROTEIN_CODING
    GuideToPharmacology Gene Category Name 2.1.1.- Methyltransferases
    GuideToPharmacology Gene Category ID 843
    (10 More Sources)

    Gene Categories: Category Details

    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    ENZYME

    Publications:

    Liu Z et al., 2009, Curcumin is a potent DNA hypomethylation agent., Bioorg Med Chem Lett
    Ghoshal et al., 2005, 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal., Mol. Cell. Biol.
    Glover et al., 1987, Biochemistry of azacitidine: a review., Cancer Treat Rep
    Silverman et al., 2002, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B., J. Clin. Oncol.
    Silverman, 2001, Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS)., Oncologist
    Ghoshal et al., 2007, DNA methyltransferases as targets for cancer therapy., Drugs Today
    Hollenbach et al., 2010, A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines., PLoS ONE
    Creusot et al., 1982, Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine., J. Biol. Chem.
    Leone et al., 2003, Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS., Clin. Immunol.
    Kaminskas et al., 2005, FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension., Oncologist
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    O'Dwyer et al., 2008, Azacitidine and the beginnings of therapeutic epigenetic modulation., Expert Opin Pharmacother
    Cataldo et al., 2009, Azacitidine for the treatment of myelodysplastic syndrome., Expert Rev Anticancer Ther
    Fenaux, 2005, Inhibitors of DNA methylation: beyond myelodysplastic syndromes., Nat Clin Pract Oncol
    Segura-Pacheco et al., 2006, Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine., J Transl Med
    Sheikh KD et al., 2010, Fluorescent epigenetic small molecule induces expression of the tumor suppressor ras-association domain family 1A and inhibits human prostate xenograft., J Med Chem
    Saba et al., 2005, Decitabine in myelodysplastic syndromes., Semin. Hematol.
    Daskalakis et al., 2010, Decitabine., Recent Results Cancer Res.
    Takebayashi et al., 2001, 5-Aza-2'-deoxycytidine induces histone hyperacetylation of mouse centromeric heterochromatin by a mechanism independent of DNA demethylation., Biochem. Biophys. Res. Commun.
    Stewart et al., 2015, KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine., Cancer Res.
    Karpf et al., 2001, Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine., Mol. Pharmacol.
    Jabbour et al., 2008, Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies., Cancer
    Csankovszki et al., 2001, Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation., J. Cell Biol.
    Ando et al., 2000, Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells., Leukemia
    Saunthararajah et al., 2003, Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease., Blood
    Oki et al., 2007, Decitabine--bedside to bench., Crit. Rev. Oncol. Hematol.
    Stresemann et al., 2008, Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine., Int. J. Cancer
    Plitta B et al., 2012, New cytosine derivatives as inhibitors of DNA methylation., Eur J Med Chem
    Wu et al., 2006, [Effect of environmental contaminants on DNA methyltransferase activity of mouse preimplantation embryos]., Wei Sheng Yan Jiu
    Sasaki et al., 1986, Effect of 5-azacytidine on the differentiation of human leukemia K-562 cells., Int. J. Cell Cloning
    Shieh et al., 2007, AdoMet-dependent methyl-transfer: Glu119 is essential for DNA C5-cytosine methyltransferase M.HhaI., J. Mol. Biol.
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Wyszynski et al., 1993, The cysteine conserved among DNA cytosine methylases is required for methyl transfer, but not for specific DNA binding., Nucleic Acids Res.
    Mutze et al., 2011, DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer., Eur. J. Cancer
    Parker et al., Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells., Cancer Biol. Ther.
    Lee et al., 2005, Procainamide is a specific inhibitor of DNA methyltransferase 1., J. Biol. Chem.
    Oelke et al., 2004, Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors., Arthritis Rheum.
    Scheinbart et al., 1991, Procainamide inhibits DNA methyltransferase in a human T cell line., J. Rheumatol.
    Januchowski et al., 2005, Effect of 5-azacytidine and procainamide on CD3-zeta chain expression in Jurkat T cells., Biomed. Pharmacother.
    Herranz et al., 2006, The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma., Blood
    Villar-Garea et al., 2003, Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells., Cancer Res.
    Li YC et al., 2018, Procaine is a specific DNA methylation inhibitor with anti-tumor effect for human gastric cancer., J Cell Biochem
    Fang et al., 2003, Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines., Cancer Res.
  • ZEBULARINE   DNMT1

    Interaction Score: 3.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16239434


    Sources:
    NCI

  • HEXAHYDROCURCUMIN   DNMT1

    Interaction Score: 3.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19112019


    Sources:
    DTC

  • CHEMBL2063052   DNMT1

    Interaction Score: 3.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22854677


    Sources:
    DTC

  • MAHANINE   DNMT1

    Interaction Score: 3.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20184324


    Sources:
    DTC

  • PALIFOSFAMIDE   DNMT1

    Interaction Score: 3.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD DrugBank

  • TETRAHYDROCURCUMIN   DNMT1

    Interaction Score: 3.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19112019


    Sources:
    DTC

  • FLUCYTOSINE   DNMT1

    Interaction Score: 3.05

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:

    PMIDs:
    17897676 17139284 17016423 8441637


    Sources:
    DrugBank

  • DECITABINE   DNMT1

    Interaction Score: 2.6

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction DNA (cytosine-5)-methyltransferase 1 inhibitor
    Direct Interaction yes
    Trial Name Dacogen/decitabine

    PMIDs:
    16015501 20072836 11688997 25968887 11259619 18398832 11352938 11752352 11069027 12907443 17023173 18425818


    Sources:
    TEND TdgClinicalTrial CIViC DrugBank ChemblInteractions

  • ANTROQUINONOL   DNMT1

    Interaction Score: 1.83

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • PROCAINAMIDE   DNMT1

    Interaction Score: 1.83

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:

    PMIDs:
    16230360 15188362 2066944 15795105


    Sources:
    DrugBank

  • GUADECITABINE   DNMT1

    Interaction Score: 1.83

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • FLUOROCYCLOPENTENYLCYTOSINE   DNMT1

    Interaction Score: 1.83

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • BISDEMETHOXYCURCUMIN   DNMT1

    Interaction Score: 1.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19112019


    Sources:
    DTC

  • AZACITIDINE   DNMT1

    Interaction Score: 0.97

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name azacitidine,Vidaza
    Novel drug target Established target
    Mechanism of Interaction DNA (cytosine-5)-methyltransferase 1 inhibitor

    PMIDs:
    2443243 12011120 11700387 17612710 20126405 6173384 14585280 15793220 11752352 18627335 19589026 16341239


    Sources:
    NCI TEND TdgClinicalTrial TTD DrugBank ChemblInteractions

  • BENZANTHRONE   DNMT1

    Interaction Score: 0.92

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DEMETHOXYCURCUMIN   DNMT1

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19112019


    Sources:
    DTC

  • PROCAINE   DNMT1

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    12941824 28926119


    Sources:
    DrugBank

  • IFOSFAMIDE   DNMT1

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    None found


    Sources:
    TEND TdgClinicalTrial

  • CHEMBL580076   DNMT1

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAPHNORIN   DNMT1

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • HYDROXYUREA   DNMT1

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2422298


    Sources:
    NCI

  • CHEMBL1490332   DNMT1

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FLOXURIDINE   DNMT1

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15899874


    Sources:
    NCI

  • ADRIAMYCIN   DNMT1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16893460


    Sources:
    NCI

  • CEPHALOTHIN   DNMT1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL599013   DNMT1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • EPIGALOCATECHIN GALLATE   DNMT1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    14633667


    Sources:
    DrugBank

  • DIETHYLSTILBESTROL   DNMT1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16598927


    Sources:
    NCI

  • MITOXANTRONE   DNMT1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12878861


    Sources:
    NCI

  • CURCUMIN   DNMT1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19112019


    Sources:
    DTC TTD

  • CISPLATIN   DNMT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21458988


    Sources:
    CIViC

  • Ensembl: ENSG00000130816

    • Version: 101_38

    Alternate Names:
    DNMT1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TEND: P26358

    • Version: 01-August-2011

    Alternate Names:
    P26358 Uniprot Accession
    DNMT1 Gene Symbol
    1786 Entrez Gene Id

    Gene Info:
    Target Main Class Enzymes
    Target Subclass 2.1.1.37

    Publications:

  • TdgClinicalTrial: P26358

    • Version: January-2014

    Alternate Names:
    DNMT1 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:2.1.1.37

    Publications:

  • GuideToPharmacology: 1786

    • Version: 29-September-2020

    Alternate Names:
    2976 HUGO Gene ID
    2976 HUGO Gene Symbol
    DNA methyltransferase 1 HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name 2.1.1.- Methyltransferases
    GuideToPharmacology Gene Category ID 843

    Gene Categories:
    ENZYME

    Publications:

  • CIViC: DNMT1

    • Version: 14-September-2020

    Alternate Names:
    1786 Entrez Gene ID
    1510 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Stewart et al., 2015, KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine., Cancer Res.
    Mutze et al., 2011, DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer., Eur. J. Cancer

  • DrugBank: BE0000892

    • Version: 5.1.7

    Alternate Names:
    DNMT1 DrugBank Gene Name
    P26358 UniProt Accession
    1786 Entrez Gene Id

    Gene Info:

    Publications:
    Villar-Garea et al., 2003, Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells., Cancer Res.
    Li YC et al., 2018, Procaine is a specific DNA methylation inhibitor with anti-tumor effect for human gastric cancer., J Cell Biochem
    Glover et al., 1987, Biochemistry of azacitidine: a review., Cancer Treat Rep

  • NCI: DNMT1

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Ghoshal et al., 2005, 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal., Mol. Cell. Biol.
    Segura-Pacheco et al., 2006, Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine., J Transl Med
    Alcock et al., 2002, Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2., Oncogene

  • DTC: DNMT1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Liu Z et al., 2009, Curcumin is a potent DNA hypomethylation agent., Bioorg Med Chem Lett
    Sheikh KD et al., 2010, Fluorescent epigenetic small molecule induces expression of the tumor suppressor ras-association domain family 1A and inhibits human prostate xenograft., J Med Chem
    Plitta B et al., 2012, New cytosine derivatives as inhibitors of DNA methylation., Eur J Med Chem

  • HingoraniCasas: ENSG00000130816

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000130816 Gene Symbol
    DNMT1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: AIM

    • Version: chembl_23

    Alternate Names:
    CXXC9 GENE_SYMBOL
    DNMT GENE_SYMBOL
    DNMT1 GENE_SYMBOL

    Gene Info:

    Publications:

  • Pharos: DNMT1

    • Version: 03-September-2020

    Alternate Names:
    DNA (cytosine-5)-methyltransferase 1 Gene Name
    P26358 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • TTD: DNA [cytosine-5]-methyltransferase

    • Version: 2020.06.01

    Alternate Names:
    DNMT TTD Gene Abbreviation
    T92308 TTD Target ID

    Gene Info:

    Publications:

  • TTD: DNA [cytosine-5]-methyltransferase 1

    • Version: 2020.06.01

    Alternate Names:
    DNMT1 TTD Gene Abbreviation
    T88304 TTD Target ID

    Gene Info:

    Publications:

  • MskImpact: DNMT1

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21